Business
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy.
About this update from Pavmed Inc.
[{"type":"text","content":"Conference Call and Webcast at 8:30 AM Eastern Time","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 financial results.","length":728,"tagName":"p"},{"type":"image","alt":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","displaySize":"","headline":null,"caption":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EIajbOKjadbArgiAenSE8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnos...